Breaking News

You are here » Indian-Commodity  :  Equity & Shares  :  Alembic Pharma rises on getting USFDA's nod for Alogliptin, Metformin Hydrochloride Tablets

14-Sep2018

Alembic Pharma rises on getting USFDA's nod for Alogliptin, Metformin Hydrochloride Tablets

Alembic Pharmaceuticals is currently trading at Rs. 647.10, up by 6.90 points or 1.08% from its previous closing of Rs. 640.20 on the BSE.

The scrip opened at Rs. 641.00 and has touched a high and low of Rs. 652.00 and Rs. 637.50 respectively. So far 7567 shares were traded on the counter.

The BSE group 'A' stock of face value Rs. 2 has touched a 52 week high of Rs. 657.00 on 12-Sep-2018 and a 52 week low of Rs. 412.40 on 24-May-2018.

Last one week high and low of the scrip stood at Rs. 657.00 and Rs. 597.55 respectively. The current market cap of the company is Rs. 12144.20 crore.

The promoters holding in the company stood at 72.96%, while Institutions and Non-Institutions held 14.30% and 12.74% respectively.

Alembic Pharmaceuticals has received tentative approval from the US Food & Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) for Alogliptin and Metformin Hydrochloride Tablets, 12.5 mg/500 mg and 12.5 mg/1000 mg. The tentatively approved ANDA is therapeutically equivalent to the reference listed drug product (RLD), KAZANO Tablets, 12.5 mg/500 mg and 12.5 mg/1000 mg of Takeda Pharma USA. Alogliptin and Metformin Hydrochloride Tablets, 12.5 mg/500 mg and 12.5 mg/1000 mg are indicated as an adjunct to diet and exercise to improve giycemic control in adults with type 2 diabetes mellitus when treatment with both alogliptin and metformin is appropriate.

Alogliptin and Metformin Hydrochloride Tablets, 12.5 mg/500 mg and 12.5 mg/1000 mg has an estimated market size of $22.5 million for twelve months ending December 2017 according to IQVIA. Alembic now has a total of 77 ANDA approvals (64 final approvals and 13 tentative approvals) from USFDA. 

Alembic Pharmaceuticals, a vertically integrated research and development pharmaceutical company, has been at the forefront of Healthcare since 1907.


Related News

View all news

Power Grid surges on getting investment approvals

Power Grid Corporation of India is currently trading at Rs. 199.20, up by 1.05 points or 0.53 % from its previous closing of Rs. 198.15 on the BSE.The scrip opened at Rs. 198.70 and has touched a high......

Palred Technologies trades in green on the BSE

Palred Technologies is currently trading at Rs. 47.90, up by 0.95 points or 2.02% from its previous closing of Rs. 46.95 on the BSE.The scrip opened at Rs. 44.90 and has touched a high and low of Rs. 47.90......

Wipro strengthens on the bourses

Wipro is currently trading at Rs. 335.40, up by 2.65 points or 0.80% from its previous closing of Rs. 332.75 on the BSE.The scrip opened at Rs. 332.65 and has touched a high and low of Rs. 336.80 and Rs.......

Top News

View all news

ABB India undertakes an ambitious project to create a high density DFC

ABB India has undertaking an ambitious project to create a high density Dedicated Freight Corridor (DFC). The DFC will run between the four cities known as the Golden Quadrilateral - Delhi, Mumbai, Chennai......

NHPC to develop 40 MW solar plant in Odisha: Report

Hydropower generation company NHPC is reportedly planning to develop 40 MW solar plant in Odisha with an investment of about Rs 196 crore. The solar power project will come up on about 180 acres of land......

Tijaria Polypipes bags order worth Rs 35.30 crore

Tijaria Polypipes has received a single order of Rs 35.30 crore for supply of HDPE & PLB Ducts from Tata Projects. The same has to be executed within a period of 3 months. The company takes great......